Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Current Deferred Revenue (2016 - 2025)

Standard Biotools (LAB) has disclosed Current Deferred Revenue for 16 consecutive years, with $42.5 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 1.15% to $42.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $42.5 million through Dec 2025, down 1.15% year-over-year, with the annual reading at $42.5 million for FY2025, 1.15% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $42.5 million at Standard Biotools, roughly flat from $42.5 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $48.5 million in Q2 2024, with the low at $11.2 million in Q3 2023.
  • Average Current Deferred Revenue over 5 years is $25.4 million, with a median of $18.0 million recorded in 2021.
  • The sharpest move saw Current Deferred Revenue soared 1088.89% in 2021, then crashed 73.28% in 2025.
  • Over 5 years, Current Deferred Revenue stood at $17.9 million in 2021, then fell by 18.45% to $14.6 million in 2022, then fell by 20.54% to $11.6 million in 2023, then surged by 270.02% to $42.9 million in 2024, then dropped by 1.15% to $42.5 million in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $42.5 million, $42.5 million, and $43.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.